Core Scientific Secures $600M JPMorgan Credit Facility to Unlock Restricted Cash

Deal Terms

Core Scientific (NASDAQ: CORZ) entered into a new credit agreement on August 25, 2026, with JPMorgan Chase Bank, N.A. serving as administrative agent and collateral agent. The facility provides the company with two distinct financing instruments: a senior secured revolving credit facility of up to $100.0 million and a letter of credit facility of up to $500.0 million, for a combined capacity of $600.0 million.

• Revolving Credit Facility: Up to $100.0 million in aggregate principal, available for borrowing, repayment, and re-borrowing
• Letter of Credit Facility: Up to $500.0 million in aggregate principal for letters of credit issuance
• Maturity: Third anniversary of the August 25, 2026 closing date, with an option for Core Scientific to extend to the fourth anniversary at its sole discretion
• Administrative Agent: JPMorgan Chase Bank, N.A., acting as both administrative and collateral agent
• Expected Cash Impact: The new financing structure is expected to release approximately $300 million in restricted cash, freeing capital for operational deployment

Why It Matters

The structure of this credit agreement is notable for what the letter of credit facility enables: rather than drawing down debt to fund operations directly, Core Scientific can use letters of credit to satisfy contractual obligations tied to its AI data center build-out, which may have previously required cash to be held in restricted accounts. The release of approximately $300 million in previously restricted cash represents a meaningful improvement in liquidity without a corresponding increase in funded debt on the balance sheet.

The one-year extension option at Core Scientific's sole discretion adds flexibility, giving the company the ability to extend its credit runway through year four without requiring lender consent. The facility's revolving structure also allows the company to manage working capital dynamically as it scales its AI infrastructure operations.

Financial Implications

Core Scientific carries $4.41 billion in total debt against $1.77 billion in total cash on its balance sheet. The addition of the $600.0 million facility increases available liquidity headroom, while the anticipated $300 million restricted cash release would materially improve the company's accessible cash position. The revolving credit facility component can be drawn and repaid repeatedly until maturity, providing ongoing operational flexibility rather than a one-time capital injection.

Wall Street View

Wall Street's stance on Core Scientific remains constructive. The most recent consensus, dated August 1, 2026, shows 23 Buy or Strong Buy ratings against 3 Hold recommendations and no Sell-side calls. No specific new price target actions were available in conjunction with this financing announcement.

Investor Takeaway

The JPMorgan credit agreement represents a structural improvement to Core Scientific's liquidity position that goes beyond the headline $600.0 million capacity: the practical near-term impact is the anticipated release of approximately $300 million in restricted cash, which converts an illiquid asset into deployable capital without new equity dilution. For a company operating at the intersection of Bitcoin mining and AI data center infrastructure, where large upfront capital commitments are common, this kind of financing flexibility could accelerate contract execution timelines. Shares traded at $17.62 on Thursday, August 27, gaining 1.15% while the S&P 500 advanced 0.66%.